A new methodology for simultaneous quantification of total-Aβ, Aβx-38, Aβx-40, and Aβx-42 by column-switching LC/MS/MS

[1]  Erin E. Chambers,et al.  Quantitation of amyloid beta peptides Aβ(1-38), Aβ(1-40), and Aβ(1-42) in human cerebrospinal fluid by ultra-performance liquid chromatography-tandem mass spectrometry. , 2011, Analytical biochemistry.

[2]  K. Heinig,et al.  An improved LC-MS/MS method for the determination of taspoglutide in plasma and urine using orthogonal HILIC-RP column switching, ultra-performance LC separation and 'wrong-way-round' electrospray ionization. , 2011, Biomedical chromatography : BMC.

[3]  P. Lewczuk,et al.  Cerebrospinal Fluid Tau, p-Tau 181 and Amyloid-β38/40/42 in Frontotemporal Dementias and Primary Progressive Aphasias , 2010, Dementia and Geriatric Cognitive Disorders.

[4]  A. Vighetto,et al.  Correlations between soluble α/β forms of amyloid precursor protein and Aβ38, 40, and 42 in human cerebrospinal fluid , 2010, Brain Research.

[5]  Xulun Zhang,et al.  Modulation of γ-Secretase Reduces β-Amyloid Deposition in a Transgenic Mouse Model of Alzheimer's Disease , 2010, Neuron.

[6]  Harald Hampel,et al.  Biological markers of amyloid β-related mechanisms in Alzheimer's disease , 2010, Experimental Neurology.

[7]  Randall J Bateman,et al.  A γ‐secretase inhibitor decreases amyloid‐β production in the central nervous system , 2009, Annals of neurology.

[8]  Otto Hudecz,et al.  Preventing carryover of peptides and proteins in nano LC-MS separations. , 2009, Analytical chemistry.

[9]  P. Lewczuk,et al.  CSF amyloid‐β 1‐38 and 1‐42 in FTD and AD: Biomarker performance critically depends on the detergent accessible fraction , 2008, Proteomics. Clinical applications.

[10]  Tetsuya Terasaki,et al.  Quantitative Atlas of Membrane Transporter Proteins: Development and Application of a Highly Sensitive Simultaneous LC/MS/MS Method Combined with Novel In-silico Peptide Selection Criteria , 2008, Pharmaceutical Research.

[11]  R. Motter,et al.  Distribution of Aβ peptide in whole blood , 2007 .

[12]  D. Holtzman,et al.  Quantitative analysis of amyloid beta peptides in cerebrospinal fluid of Alzheimer's disease patients by immunoaffinity purification and stable isotope dilution liquid chromatography/negative electrospray ionization tandem mass spectrometry. , 2006, Rapid communications in mass spectrometry : RCM.

[13]  Tracy M. Brown,et al.  Concentration-Dependent Modulation of Amyloid-β in Vivo and in Vitro Using the γ-Secretase Inhibitor, LY-450139 , 2006, Journal of Pharmacology and Experimental Therapeutics.

[14]  S. Weggen,et al.  Selective modulation of Abeta42 production in Alzheimer's disease: non-steroidal anti-inflammatory drugs and beyond. , 2006, Current pharmaceutical design.

[15]  T. Lanz,et al.  Demonstration of a common artifact in immunosorbent assays of brain extracts: Development of a solid-phase extraction protocol to enable measurement of amyloid-β from wild-type rodent brain , 2006, Journal of Neuroscience Methods.

[16]  Takao Shimizu,et al.  A multiplex quantitation method for eicosanoids and platelet-activating factor using column-switching reversed-phase liquid chromatography-tandem mass spectrometry. , 2005, Analytical biochemistry.

[17]  A. Nadin,et al.  Quantitative Measurement of Changes in Amyloid-β(40) in the Rat Brain and Cerebrospinal Fluid following Treatment with the γ-Secretase Inhibitor LY-411575 [N2-[(2S)-2-(3,5-Difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-l-alaninamide] , 2005, Journal of Pharmacology and Experimental Therapeutics.

[18]  M. Dadlez,et al.  Alzheimer's disease Abeta peptide fragment 10-30 forms a spectrum of metastable oligomers with marked preference for N to N and C to C monomer termini proximity. , 2004, Journal of molecular biology.

[19]  E. Zamrini,et al.  Autoimmunity in Alzheimer’s disease: increased levels of circulating IgGs binding Aβ and RAGE peptides , 2004, Neurobiology of Aging.

[20]  L. Cohen,et al.  Quantitation of endogenous analytes in biofluid without a true blank matrix. , 2003, Analytical chemistry.

[21]  Mohammed Jemal,et al.  Liquid chromatography/tandem mass spectrometry methods for quantitation of mevalonic acid in human plasma and urine: method validation, demonstration of using a surrogate analyte, and demonstration of unacceptable matrix effect in spite of use of a stable isotope analog internal standard. , 2003, Rapid communications in mass spectrometry : RCM.

[22]  Pritam Das,et al.  NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo , 2003 .

[23]  A. Delacourte,et al.  Truncated beta‐amyloid peptide species in pre‐clinical Alzheimer's disease as new targets for the vaccination approach , 2003, Journal of neurochemistry.

[24]  G. Krafft,et al.  In Vitro Characterization of Conditions for Amyloid-β Peptide Oligomerization and Fibrillogenesis* , 2003, The Journal of Biological Chemistry.

[25]  L. Tjernberg,et al.  Assembling amyloid fibrils from designed structures containing a significant amyloid beta-peptide fragment. , 2002, The Biochemical journal.

[26]  T. Konakahara,et al.  Identification of the molecular interaction site of amyloid beta peptide by using a fluorescence assay. , 2001, The journal of peptide research : official journal of the American Peptide Society.

[27]  W. Oertel,et al.  Reduced levels of amyloid β-peptide antibody in Alzheimer disease , 2001, Neurology.

[28]  D. Galasko,et al.  Amyloid-beta peptides interact with plasma proteins and erythrocytes: implications for their quantitation in plasma. , 2000, Biochemical and biophysical research communications.

[29]  Tetsuya Terasaki,et al.  Simultaneous absolute quantification of 11 cytochrome P450 isoforms in human liver microsomes by liquid chromatography tandem mass spectrometry with in silico target peptide selection. , 2011, Journal of pharmaceutical sciences.